GlassScriptPhysician profile
Veronica W Chang
NPI 1346524691
$11,535.15
in general payments reported to CMS, 2019-2025
35 companies · $4,323 in 2025
The $4,323 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $473 · 2022: $1,493 · 2023: $2,086 · 2024: $3,161 · 2025: $4,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,374 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,373.77 |
| Education | $195.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,622.51 | 2021-2025 | |
| Genzyme Corporation | $1,316.68 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,076.46 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $918.33 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $694.52 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $551.85 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Incyte Corporation | $530.08 | 2021-2025 | Opzelura |
| Pfizer INC. | $516.79 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $480.36 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $467.25 | 2021-2025 | |
| Galderma Laboratories, L.P. | $445.53 | 2021-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $432.90 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $361.38 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $345.59 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $339.65 | 2021-2025 | Odomzo, Blu-U, Winlevi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $280.16 | 2022-2025 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.87 | 2022-2025 | Spevigo |
| Journey Medical Corporation | $124.73 | 2021-2025 | |
| Medtronic, INC. | $117.16 | 2022 | |
| Merz North America, INC. | $116.86 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $97.94 | 2021-2025 | |
| Biofrontera INC. | $86.56 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Verrica Pharmaceuticals INC. | $62.13 | 2023-2024 | Ycanth |
| Fresenius Kabi USA, LLC | $51.90 | 2023-2024 | |
| Kyowa Kirin, INC. | $50.44 | 2023-2024 | Poteligeo |
| Blueprint Medicines Corporation | $36.13 | 2025 | Ayvakit |
| Botanix Sb INC | $28.06 | 2025 | Sofdra |
| Sandoz INC. | $27.06 | 2024 | Hyrimoz |
| Revance Therapeutics, INC. | $25.68 | 2024 | Daxxify |
| Lifenet Health | $25.56 | 2023 | |
| Lnhc, INC | $23.44 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.35 | 2025 | Cabtreo, Jublia, Siliq |
| Solta Medical, A Division of Bausch Health US, LLC | $19.30 | 2024 | Clear & Brilliant, Fraxel |
| Strata Skin Sciences, INC. | $17.62 | 2025 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $14.32 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.